Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00559533 · ClinicalTrials.gov registry record · Phase 1
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT00559533 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 106 participants.
The verdict
NCT00559533, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
This study will determine the maximum tolerated dose and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with advanced solid tumors. A first cohort of patients will receive the starting dose of 20mg/m2/day, once daily for 10 days in each 28 day cycle. Subsequent cohorts of patients will receive dose escalations, and possible changes in dosing schedule, based on tolerability and pharmacokinetic knowledge gained from prior treatment cohorts. The anticipated time on study treatment is until disease progression or intolerable toxicity.
Interventions
- DRUG RO5045337
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2007-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00559533
The ClinicalTrials.gov registry entry for NCT00559533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO5045337 is the first listed.
NCT00559533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00559533 about?
NCT00559533 is a clinical study titled "A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors". This study will determine the maximum tolerated dose and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with advanced solid tumors. A first cohort of patients will receive the starting dose of 20mg/m2/day, once daily for 10 days in each 28 day c...
What is the current status of trial NCT00559533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2007-12. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00559533?
The interventions under investigation include: RO5045337 (DRUG).
Who is sponsoring clinical trial NCT00559533?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.